Cargando…

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach

INTRODUCTION: Clinical studies demonstrate an accelerated decline in lung function in patients with moderate chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease [GOLD] grade 2) versus severe and very severe COPD (GOLD grades 3 and 4). This predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Litewka, Diego, Páramo, Rafael, Rendon, Adrian, Sayiner, Abdullah, Tanni, Suzana E., Acharya, Sudeep, Aggarwal, Bhumika, Ismaila, Afisi S., Sharma, Raj, Daley-Yates, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499693/
https://www.ncbi.nlm.nih.gov/pubmed/37382864
http://dx.doi.org/10.1007/s12325-023-02583-1
_version_ 1785105761108492288
author Singh, Dave
Litewka, Diego
Páramo, Rafael
Rendon, Adrian
Sayiner, Abdullah
Tanni, Suzana E.
Acharya, Sudeep
Aggarwal, Bhumika
Ismaila, Afisi S.
Sharma, Raj
Daley-Yates, Peter
author_facet Singh, Dave
Litewka, Diego
Páramo, Rafael
Rendon, Adrian
Sayiner, Abdullah
Tanni, Suzana E.
Acharya, Sudeep
Aggarwal, Bhumika
Ismaila, Afisi S.
Sharma, Raj
Daley-Yates, Peter
author_sort Singh, Dave
collection PubMed
description INTRODUCTION: Clinical studies demonstrate an accelerated decline in lung function in patients with moderate chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease [GOLD] grade 2) versus severe and very severe COPD (GOLD grades 3 and 4). This predictive modelling study assessed the impact of initiating pharmacotherapy earlier versus later on long-term disease progression in COPD. METHODS: The modelling approach used data on decline in forced expiratory volume in 1 s (FEV(1)) extracted from published studies to develop a longitudinal non-parametric superposition model of lung function decline with progressive impact of exacerbations from 0 per year to 3 per year and no ongoing pharmacotherapy. The model simulated decline in FEV(1) and annual exacerbation rates from age 40 to 75 years in COPD with initiation of long-acting anti-muscarinic antagonist (LAMA)/long-acting beta(2)-agonist (LABA) (umeclidinium (UMEC)/vilanterol (VI)) or triple (inhaled corticosteroid (ICS)/LAMA/LABA; fluticasone furoate (FF)/UMEC/VI) therapy at 40, 55 or 65 years of age. RESULTS: Model-predicted decline in FEV(1) showed that, compared with ‘no ongoing’ therapy, initiation of triple or LAMA/LABA therapy at age 40, 55 or 65 years preserved an additional 469.7 mL or 236.0 mL, 327.5 mL or 203.3 mL, or 213.5 mL or 137.5 mL of lung function, respectively, by the age of 75. The corresponding average annual exacerbation rates were reduced from 1.57 to 0.91, 1.06 or 1.23 with triple therapy or to 1.2, 1.26 and 1.4 with LAMA/LABA therapy when initiated at 40, 55 or 65 years of age, respectively. CONCLUSIONS: This modelling study suggests that earlier initiation of LAMA/LABA or triple therapy may have positive benefits in slowing disease progression in patients with COPD. Greater benefits were demonstrated with early initiation therapy with triple versus LAMA/LABA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02583-1.
format Online
Article
Text
id pubmed-10499693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-104996932023-09-15 DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach Singh, Dave Litewka, Diego Páramo, Rafael Rendon, Adrian Sayiner, Abdullah Tanni, Suzana E. Acharya, Sudeep Aggarwal, Bhumika Ismaila, Afisi S. Sharma, Raj Daley-Yates, Peter Adv Ther Original Research INTRODUCTION: Clinical studies demonstrate an accelerated decline in lung function in patients with moderate chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease [GOLD] grade 2) versus severe and very severe COPD (GOLD grades 3 and 4). This predictive modelling study assessed the impact of initiating pharmacotherapy earlier versus later on long-term disease progression in COPD. METHODS: The modelling approach used data on decline in forced expiratory volume in 1 s (FEV(1)) extracted from published studies to develop a longitudinal non-parametric superposition model of lung function decline with progressive impact of exacerbations from 0 per year to 3 per year and no ongoing pharmacotherapy. The model simulated decline in FEV(1) and annual exacerbation rates from age 40 to 75 years in COPD with initiation of long-acting anti-muscarinic antagonist (LAMA)/long-acting beta(2)-agonist (LABA) (umeclidinium (UMEC)/vilanterol (VI)) or triple (inhaled corticosteroid (ICS)/LAMA/LABA; fluticasone furoate (FF)/UMEC/VI) therapy at 40, 55 or 65 years of age. RESULTS: Model-predicted decline in FEV(1) showed that, compared with ‘no ongoing’ therapy, initiation of triple or LAMA/LABA therapy at age 40, 55 or 65 years preserved an additional 469.7 mL or 236.0 mL, 327.5 mL or 203.3 mL, or 213.5 mL or 137.5 mL of lung function, respectively, by the age of 75. The corresponding average annual exacerbation rates were reduced from 1.57 to 0.91, 1.06 or 1.23 with triple therapy or to 1.2, 1.26 and 1.4 with LAMA/LABA therapy when initiated at 40, 55 or 65 years of age, respectively. CONCLUSIONS: This modelling study suggests that earlier initiation of LAMA/LABA or triple therapy may have positive benefits in slowing disease progression in patients with COPD. Greater benefits were demonstrated with early initiation therapy with triple versus LAMA/LABA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02583-1. Springer Healthcare 2023-06-29 2023 /pmc/articles/PMC10499693/ /pubmed/37382864 http://dx.doi.org/10.1007/s12325-023-02583-1 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Singh, Dave
Litewka, Diego
Páramo, Rafael
Rendon, Adrian
Sayiner, Abdullah
Tanni, Suzana E.
Acharya, Sudeep
Aggarwal, Bhumika
Ismaila, Afisi S.
Sharma, Raj
Daley-Yates, Peter
DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
title DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
title_full DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
title_fullStr DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
title_full_unstemmed DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
title_short DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
title_sort delaying disease progression in copd with early initiation of dual bronchodilator or triple inhaled pharmacotherapy (depict): a predictive modelling approach
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499693/
https://www.ncbi.nlm.nih.gov/pubmed/37382864
http://dx.doi.org/10.1007/s12325-023-02583-1
work_keys_str_mv AT singhdave delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT litewkadiego delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT paramorafael delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT rendonadrian delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT sayinerabdullah delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT tannisuzanae delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT acharyasudeep delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT aggarwalbhumika delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT ismailaafisis delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT sharmaraj delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach
AT daleyyatespeter delayingdiseaseprogressionincopdwithearlyinitiationofdualbronchodilatorortripleinhaledpharmacotherapydepictapredictivemodellingapproach